Gastrointestinal hormone measurably improved symptoms of non-alcoholic fatty liver disease

Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The findings represent an important proof-of-concept for the compound as there are currently no Food and Drug Administration-approved treatments for NAFLD and NASH.

This post was syndicated from Top Health News -- ScienceDaily. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply